<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Imaging</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Imaging</journal-id><journal-title-group><journal-title>Cancer Imaging</journal-title></journal-title-group><issn pub-type="ppub">1740-5025</issn><issn pub-type="epub">1470-7330</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1470-7330-14-S1-O9</article-id><article-id pub-id-type="doi">10.1186/1470-7330-14-S1-O9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oral Presentation</subject></subj-group></article-categories><title-group><article-title>MRI for managing intermediate &#x00026; low risk prostate cancer</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Padhani</surname><given-names>Anwar R</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>anwar.padhani@stricklandscanner.org.uk</email></contrib></contrib-group><aff id="I1"><label>1</label>Mount Vernon Cancer Centre, London, UK</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>9</day><month>10</month><year>2014</year></pub-date><volume>14</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Proceedings of the International Cancer Imaging Society (ICIS) 14th Annual Teaching Course</named-content><named-content content-type="supplement-sponsor">Publication charges for this supplement were funded through the International Cancer Imaging Society by support received from Siemens AG, Healthcare Sector, Imaging and Therapy Division.</named-content></supplement><fpage>O9</fpage><lpage>O9</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Padhani; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Padhani; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.cancerimagingjournal.com/content/14/S1/O9"/><conference><conf-date>9-11 October 2014</conf-date><conf-name>International Cancer Imaging Society (ICIS) 14th Annual Teaching Course</conf-name><conf-loc>Heidelberg, Germany</conf-loc></conference></article-meta></front><body><sec><title>Intermediate risk disease</title><p>Pathological status: PSA 10&#x02013;20 ng/mL, <bold>or</bold> biopsy Gleason score 7, <bold>or</bold> clinical stage T2b or T2c</p><p>Clinical note: Heterogeneous group with a wide incidence of biochemical relapse &#x00026; numerous curative therapy options.</p><p>Problems with categorization: Detection of unfavourable subgroup includes Gleason &#x02265;4+3 <italic>and/or</italic> &#x0003e;50% positive biopsies <italic>and/or</italic> &#x0003e;1 intermediate risk factors [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]</p><p>Role of MRI in practice:</p><p>1. If initial active surveillance is considered, then it is important not to underestimate tumor grade/ volume/stage</p><p>2. For external beam radiotherapy, the presence of unfavourable disease affects duration of adjuvant hormonal therapy.</p><p>3. For focal therapy, index lesion localization is needed</p><p>4. For surgery, accurate staging to enable curative treatment with negative margins &#x00026; nerve sparing if possible</p><p>Type of MRI [<xref ref-type="bibr" rid="B3">3</xref>]:</p><p>&#x02022; Lesion detection and localisation protocol with T2W, DW-MRI and DCE-MRI &#x000b1; MRSI for low ADC lesions to assess aggressiveness</p><p>&#x02022; Staging with multi-planar T2W, DW-MRI &#x000b1; DCE-MRI for ECE/SVI</p></sec><sec><title>High risk disease</title><p>Pathological status: PSA &#x0003e;20 ng/mL, <bold>or</bold> Gleason score 8&#x02013;10, <bold>or</bold> clinical stage &#x0003e;T2c</p><p>Clinical note: Highest risk of biochemical recurrence and cancer specific mortality but substantial population heterogeneity</p><p>Prognostic subgroups [<xref ref-type="bibr" rid="B4">4</xref>]:</p><p>&#x025a0; Good prognosis subgroup: one single risk factor (any)</p><p>&#x025a0; Intermediate prognosis subgroup: two risk factors (PSA &#x0003e;20 ng/ml and stage cT3&#x02013;4); <bold>No</bold> Gleason 8+ disease</p><p>&#x025a0; Poor prognosis subgroup: GS &#x0003e;7 and stage cT3&#x02013;4 and/or PSA &#x0003e;20 ng/ml</p><p>Clinical sub-groups: localized, locally advanced &#x00026; metastatic</p><p>Problems with categorization: Local staging accuracy &#x00026; the detection of metastatic disease</p><p>Role of MRI in practice</p><p>1. local and nodal staging: to detect extensive ECE/SVI that would preclude radical surgery with negative margins. Nerve sparing rarely undertaken.</p><p>2. To detect nodal and bone metastases</p><p>Type of MRI [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref>]:</p><p>&#x02022; Accurate local staging and pelvic nodal assessments</p><p>&#x02022; Bone scan + CT abdomen or WB-MRI</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>D'Amico</surname><given-names>AV</given-names></name><article-title>Personalizing the management of men with intermediate-risk prostate cancer</article-title><source>Eur Urol</source><year>2013</year><volume>64</volume><issue>6</issue><fpage>903</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2013.03.038</pub-id><?supplied-pmid 23545122?><pub-id pub-id-type="pmid">23545122</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Keane</surname><given-names>FK</given-names></name><name><surname>Chen</surname><given-names>MH</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Loffredo</surname><given-names>MJ</given-names></name><name><surname>Kantoff</surname><given-names>PW</given-names></name><name><surname>Renshaw</surname><given-names>AA</given-names></name><name><surname>D'Amico</surname><given-names>AV</given-names></name><article-title>The likelihood of death from prostate cancer in men with favorable or unfavourable intermediate-risk disease</article-title><source>Cancer</source><year>2014</year><volume>120</volume><issue>12</issue><fpage>1787</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1002/cncr.28609</pub-id><?supplied-pmid 24604289?><pub-id pub-id-type="pmid">24604289</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Cornud</surname><given-names>F</given-names></name><name><surname>Delongchamps</surname><given-names>NB</given-names></name><name><surname>Mozer</surname><given-names>P</given-names></name><name><surname>Beuvon</surname><given-names>F</given-names></name><name><surname>Schull</surname><given-names>A</given-names></name><name><surname>Muradyan</surname><given-names>N</given-names></name><name><surname>Peyromaure</surname><given-names>M</given-names></name><article-title>Value of multiparametric MRI in the work-up of prostate cancer</article-title><source>Curr Urol Rep</source><year>2012</year><volume>13</volume><issue>1</issue><fpage>82</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1007/s11934-011-0231-z</pub-id><?supplied-pmid 22139624?><pub-id pub-id-type="pmid">22139624</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Joniau</surname><given-names>S</given-names></name><name><surname>Briganti</surname><given-names>A</given-names></name><name><surname>Gontero</surname><given-names>P</given-names></name><name><surname>Gandaglia</surname><given-names>G</given-names></name><name><surname>Tosco</surname><given-names>L</given-names></name><name><surname>Fieuws</surname><given-names>S</given-names></name><name><surname>Tombal</surname><given-names>B</given-names></name><name><surname>Marchioro</surname><given-names>G</given-names></name><name><surname>Walz</surname><given-names>J</given-names></name><name><surname>Kneitz</surname><given-names>B</given-names></name><name><surname>Bader</surname><given-names>P</given-names></name><name><surname>Frohneberg</surname><given-names>D</given-names></name><name><surname>Tizzani</surname><given-names>A</given-names></name><name><surname>Graefen</surname><given-names>M</given-names></name><name><surname>van Cangh</surname><given-names>P</given-names></name><name><surname>Karnes</surname><given-names>RJ</given-names></name><name><surname>Montorsi</surname><given-names>F</given-names></name><name><surname>Van Poppel</surname><given-names>H</given-names></name><name><surname>Spahn</surname><given-names>M</given-names></name><article-title>European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study</article-title><source>Eur Urol</source><year>2014</year><volume>S0302-2838</volume><issue>14</issue><fpage>00071</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2014.01.020</pub-id><?supplied-pmid 24486307?><pub-id pub-id-type="pmid">24486307</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Lecouvet</surname><given-names>FE</given-names></name><name><surname>Lhommel</surname><given-names>R</given-names></name><name><surname>Pasoglou</surname><given-names>V</given-names></name><name><surname>Larbi</surname><given-names>A</given-names></name><name><surname>Jamar</surname><given-names>F</given-names></name><name><surname>Tombal</surname><given-names>B</given-names></name><article-title>Novel imaging techniques reshape the landscape in high-risk prostate cancers</article-title><source>Curr Opin Urol</source><year>2013</year><volume>23</volume><issue>4</issue><fpage>323</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1097/MOU.0b013e328361d451</pub-id><?supplied-pmid 23619580?><pub-id pub-id-type="pmid">23619580</pub-id></mixed-citation></ref></ref-list></back></article>
